INSMED Inc (INSM) Form 10-Q — Oct 29, 2026
Insmed's Q3 2026 revenue hit $524.4 million, up 268% year over year, driven almost entirely by the US launch of BRINSUPRI, which generated $398.1 million in the quarter. Nine-month revenue reached $1.256 billion versus $342.6 million a year ago. The company is still loss-making but improving fast: Q3 net loss narrowed to $100.3 million from $370.0 million a year earlier, and nine-month operating cash burn fell to $348 million from $687 million. Insmed holds roughly $1.15 billion in cash and marketable securities against a $500 million term loan at 9.6%.
Key figures
- Revenue
- 1255878000
- Total Debt
- $500.0M Term Loans principal (9.6% fixed rate)
- Revenue Yoy
- 267% (nine months: $1,255.9M vs $342.6M)
- Total Assets
- 2226056000
- Cash Position
- $396.6M cash plus $750.1M marketable securities
- Shares Outstanding
- 219320467
- Q3 2026 eps
- -$0.46
- Q3 2026 revenue
- $524.4M (up 268% YoY from $142.3M)
- Working capital
- $1.1B
- Q3 2026 net loss
- -$100.3M (vs -$370.0M year-ago)
- Cfo departure date
- 2026-10-30
- Arikayce 9m revenue
- ~$338.8M implied total minus BRINSUPRI; MD&A cites $24.3M growth
- Brinsupri 9m revenue
- $917.1M (US $913.8M)
- Operating cash burn 9m
- -$348.0M (vs -$687.4M year-ago)
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.